References
- Cefalu WT. Insulin resistance: Cellular and clinical concepts. Exp Biol Med. 2001;226(1):13–26.10.1177/15353702012260010311368233
- Zapata-Bustos R, Finlayson J, Langlais PR, Coletta DK, Luo M, Grandjean D, et al. Altered transcription factor expression responses to exercise in insulin resistance. Front Physiol. 2021;12:649461.10.3389/fphys.2021.649461805836833897458
- Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev. 2019;40(6):1447-67.10.1210/er.2018-00141744541931050706
- Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019;1(4):312-28.10.1016/j.jhepr.2019.07.002700155732039382
- Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-34.10.1016/j.pcd.2021.04.004803125933849817
- Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1-58.10.1002/cphy.c110062412966123720280
- Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(2):S112-9.10.2337/dc07-s20217596458
- Kelsey MM, Zeitler PS. Insulin Resistance of Puberty. Curr Diab Rep. 2016;16(7):64.10.1007/s11892-016-0751-527179965
- Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: A review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708.10.1016/j.biopha.2020.11070832927252
- Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2011;73(04):460-6.10.4088/JCP.10m0682222225552
- Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol. 2018;175:177-89.10.1016/j.jsbmb.2016.09.01727662816
- Rudvik A, Månsson M. Evaluation of surrogate measures of insulin sensitivity - correlation with gold standard is not enough. BMC Med Res Methodol. 2018;18(1):64.10.1186/s12874-018-0521-y601983129940866
- Lee CH, Shih AZ, Woo YC, et al. Optimal Cut-Offs of Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) to Identify Dysglycemia and Type 2 Diabetes Mellitus: A 15-Year Prospective Study in Chinese. PLoS One. 2016;11(9):e0163424.10.1371/journal.pone.0163424503357027658115
- Singh Y, Garg MK, Tandon N, Marwaha RK. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5(4):245-51.10.4274/Jcrpe.1127389022424379034
- Alebić MŠ, Bulum T, Stojanović N, Duvnjak L. Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine. 2014;47(2):625-30.10.1007/s12020-014-0182-524522614
- Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010;1(2):36-47.10.4239/wjd.v1.i2.36308388421537426
- Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch. 2020;472(9):1273-98.10.1007/s00424-020-02417-x746292432591906
- DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(2):S157-S163.10.2337/dc09-S302281143619875544
- Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315.10.1016/j.biopha.2021.11131533561645
- Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004;33(2):431-53.10.1016/j.ecl.2004.03.00815158528
- Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121.10.1186/s12944-015-0123-1
- Bazotte RB, Silva LG, Schiavon FP. Insulin resistance in the liver: deficiency or excess of insulin?. Cell Cycle. 2014;13(16):2494-500.10.4161/15384101.2014.947750
- Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33(2):283-303.10.1016/j.ecl.2004.03.002
- Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. Sci. World J. 2015;2015:479354.
- Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J CardioMetab Syndr. 2009;4(2):113–9.10.1111/j.1559-4572.2008.00044.x
- Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived? Diabetes Care. 2017;40(7):813–20.10.2337/dc16-2736
- Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(6a):9S–14S.10.1016/S0002-9343(00)00337-5
- Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. J Endocr Soc. 2019;3(9):1727-47.10.1210/js.2019-00065673575931528832
- Jung SH, Jung CH, Reaven GM, Kim SH. Adapting to insulin resistance in obesity: role of insulin secretion and clearance. Diabetologia. 2018;61(3):681-7.10.1007/s00125-017-4511-0609513729196782
- Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91.10.1210/jc.2005-033116076947
- Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V et al. Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest. 2002;25(6):532–8.10.1007/BF0334549612109625
- Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC et al. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab. 2015;100(8):2946-55.10.1210/jc.2015-1917452499426037515
- Winhofer Y, Wolf P, Krššák M, Wolfsberger S, Tura A, Pacini G et al. No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2014;99(11):4299-306.10.1210/jc.2014-224225148232
- Vila G, Jørgensen JOL, Luger A, Stalla GK. Insulin Resistance in Patients With Acromegaly. Front Endocrinol (Lausanne). 2019;10:509.10.3389/fendo.2019.00509668366231417493
- Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.10.2337/db09-9028266158219336687
- Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52(5):549-55.10.1046/j.1365-2265.2000.00986.x10792333
- Rogowicz-Frontczak A, Majchrzak A, Zozulińska-Ziółkiewicz D. Insulin resistance in endocrine disorders - treatment options. Endokrynol Pol. 2017;68(3):334-51.10.5603/EP.2017.002628660991
- Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97(5):1702–11.10.1210/jc.2011-3123333989022419708
- Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002;290(3):1084-9.10.1006/bbrc.2001.630711798186
- Gierach M, Gierach J, Junik R. Insulin resistance and thyroid disorders. Endokrynol Pol. 2014;65:70-6.10.5603/EP.2014.001024549605
- B UU, Mn S, Km S, Prashant A, Doddamani P, Sv S. Effect of insulin resistance in assessing the clinical outcome of clinical and subclinical hypothyroid patients. J Clin Diagn Res. 2015;9(2):OC01-OC4.10.7860/JCDR/2015/9754.5513437875925859477
- Vyakaranam S, Vanaparthy S, Nori S, Palarapu S, Bhongir AV. Study of Insulin Resistance in Subclinical Hypothyroidism. Int J Health Sci Res. 2014;4(9):147-53.
- Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf). 2008;69(6):963–9.10.1111/j.1365-2265.2008.03280.x18429948
- Harikrishna A, Ishak A, Ellinides A, Saad R, Christodoulou H, Spartalis E, et al. The impact of obesity and insulin resistance on thyroid cancer: A systematic review. Maturitas. 2019;125:45-9.10.1016/j.maturitas.2019.03.02231133216
- Balkan F, Onal ED, Usluogullari A, Tuzun D, Ozdemir D, Inancli SS, et al. „Is there any association between insulin resistance and thyroid cancer? : A case control study”. Endocrine. 2014;45(1):55–60.10.1007/s12020-013-9942-x23564559
- Heidari Z, Abdani M, Mansournia MA. Insulin Resistance Associated With Differentiated Thyroid Carcinoma: Penalized Conditional Logistic Regression Analysis of a Matched Case-Control Study Data. Int J Endocrinol Metab. 2017;16(1):e14545.10.5812/ijem.14545590338229696038
- Klubo-Gwiezdzinska J, Costello J, Patel A, Bauer A, Jensen K, Mete M, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013;98(8):3269–79.10.1210/jc.2012-379923709654
- Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. Int J Adolesc Med Health. 2021 Jul 22 [published online ahead of print]. DOI: 10.1515/ijamh-2021-0073.10.1515/ijamh-2021-007334293835
- Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014;2:56.
- Moghetti P. Insulin Resistance and Polycystic Ovary Syndrome. Curr Pharm Des. 2016;22(36):5526-34.10.2174/138161282266616072015585527510482
- Li H, Chen Y, Yan LY, Qiao J. Increased expression of P450scc and CYP17 in development of endogenous hyperandrogenism in a rat model of PCOS. Endocrine. 2013;43(1):184-90.10.1007/s12020-012-9739-322798247
- Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol. 2016;16(1):53-60.10.1016/j.repbio.2015.12.00626952754
- Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21.10.1016/j.cca.2019.11.00331733195
- Al-Sulaiti H, Diboun I, Agha MV, Mohamed FF, Atkin S, Dömling AS, et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J Transl Med. 2019;17(1):348.10.1186/s12967-019-2096-8
- Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. Front Endocrinol (Lausanne). 2019;10:703.10.3389/fendo.2019.00703
- Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007;30(5):1200-5.10.2337/dc06-2416
- Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353):226-8.10.1016/S0140-6736(03)12255-6
- McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet. 2002;359(9300):46-7.10.1016/S0140-6736(02)07281-1
- Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21(3):403-16.10.1016/j.cmet.2015.02.006
- Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11(6):212-7.10.1016/S1043-2760(00)00272-1
- Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020;10:1607.10.3389/fphys.2019.01607700065732063863
- Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(1):E146-E150.10.1210/jc.2010-1170303848121047923
- Chen CC, Kuo CH, Leu YL, Wang SH. Corylin reduces obesity and insulin resistance and promotes adipose tissue browning through SIRT-1 and β3-AR activation. Pharmacol Res. 2021;164:105291.10.1016/j.phrs.2020.10529133253817
- Kobyliak, N., Falalyeyeva, T., Mykhalchyshyn, Molochek N, Savchuk O, Kyriienko D, et al. Probiotic and omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance, improves glycemia and obesity parameters in individuals with type 2 diabetes: A randomised controlled trial. Obesity Medicine. 2020;19:100248.10.1016/j.obmed.2020.100248
- Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.10.1186/1758-5996-5-6360788923415113
- Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019;19(12):151.10.1007/s11892-019-1270-y688142931776781
- Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13(1):23.10.1186/s13098-021-00639-2791999933648564
- Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte. 2018;7(2):121-28.
- Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci. 2020;240:117090.10.1016/j.lfs.2019.11709031765648
- Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299-308.10.1111/1471-0528.1475428544572